|
Getting your Trinity Audio player ready...
|
Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.
Health In Tech (NASDAQ: HIT) and DialCare to expand its self-funded health plans, providing nationwide virtual access to primary care, therapy, and psychiatry via its advanced eDIYBS platform. Health In Tech is a disruptive Insurtech platform company leveraging third-party AI technologies to streamline the healthcare insurance process through vertical integration, automation, and digital transformation. The company empowers TPAs, brokers, and carriers with tools that simplify underwriting, sales, and claims processing—ultimately driving efficiency in the self-funded healthcare space.
OSR Holdings’ (NASDAQ: OSRH), subsidiary Vaximm AG announced successful Phase 2a results for its oral cancer vaccine VXM01 in combination with avelumab, demonstrating a strong safety profile and potential clinical benefit in recurrent glioblastoma patients.
Theratechnologies (NASDAQ: THTX), secured FDA approval for EGRIFTA WR™, a new formulation of tesamorelin to treat excess abdominal fat in adults with HIV and lipodystrophy. The once-weekly reconstitution improves patient convenience while maintaining bioequivalence.
Leap Therapeutics (NASDAQ: LPTX) reported positive Phase 2 data for sirexatamab (DKN-01), its anti-DKK1 antibody, in advanced colorectal cancer. Patients with high DKK1 levels or no prior anti-VEGF therapy showed significantly improved response rates and progression-free survival, supporting the potential for a registrational trial.
Together, these companies exemplify a dynamic convergence of tech-enabled care, targeted biologics, and breakthrough therapies aimed at improving patient outcomes across multiple fronts of the healthcare landscape.
CS Diagnostics Corp. (OTCQB: CSDX) operates in the Medical Device & Biotechnology sector, specializing in radiation oncology solutions. The company focuses on advanced hydrogel technologies for cancer treatment, positioning itself within the broader healthcare and life sciences industry.